Prevention of RSV bronchiolitis: reassuring safety profile, persistent medication errors
ANSM surveillance report on RSV bronchiolitis prevention medication safety profile and ongoing medication error patterns.
ANSM (French Medicine Agency) · FranceANSM (French Medicine Agency)
Regulation
Category
Type
Date
Third pharmacovigilance report on aGLP-1 agents: persistence of misuse associated with serious complications and evidence of drug interaction risk
Third pharmacovigilance report on GLP-1 agonists identifies ongoing misuse causing serious complications and new drug interaction risks.
ANSM (French Medicine Agency) · FranceExtending the shelf life of medicines to reduce waste and pollution
ANSM guidance on extending medicine shelf life to reduce pharmaceutical waste and environmental impact.
ANSM (French Medicine Agency) · FranceANSM activates 2026-2027 winter monitoring plan for medicines and medical devices
PUBLIÉ LE 13/10/2026 - MIS À JOUR LE 16/10/2026 L’ANSM active le plan 2026-2027 de suivi des médicaments et des dispositifs médicaux de l’hiver Disponibilité des produits de santé Médicaments
ANSM (French Medicine Agency) · FranceDesogestrel-based contraception and meningioma risk: questions and answers
ANSM provides Q&A guidance on the safety signal linking desogestrel-based contraceptive products to meningioma risk.
ANSM (French Medicine Agency) · FranceInfluenza, COVID-19, bronchiolitis: protecting against winter respiratory infections
ANSM advises on prevention of winter respiratory infections through vaccination, RSV protection for infants, and barrier measures.
ANSM (French Medicine Agency) · FranceANSM distributes personalized letter informing women of very low meningioma risk associated with desogestrel-based contraception
ANSM issues direct healthcare professional communication on very low meningioma risk associated with desogestrel-based contraceptive products.
ANSM (French Medicine Agency) · FranceANSM achieves 98/100 score on professional equality index 2025
PUBLIÉ LE 18/09/2026 L'ANSM obtient le score de 98/100 pour son index de l’égalité professionnelle 2025 Vie de l’Agence Publications institutionnelles
ANSM (French Medicine Agency) · FranceCancer treatments: measures implemented following national inquiry in health facilities strengthen safety of patients receiving fluoropyrimidine chemotherapy
ANSM reports on safety measures implemented across health facilities following a national inquiry into fluoropyrimidine chemotherapy administration.
ANSM (French Medicine Agency) · FranceOnline-sold 'peptides': do not use them, they may be dangerous
ANSM warns against peptides sold online, identifying them as unsafe products posing health risks.
ANSM (French Medicine Agency) · FranceFluoropyrimidine-based chemotherapies (capecitabine and 5-FU): monitor adverse effects and adjust doses
ANSM advises monitoring adverse effects and dose adjustment for fluoropyrimidine-based chemotherapies (capecitabine and 5-FU).
ANSM (French Medicine Agency) · FranceDuloxetine: ANSM requests manufacturers to strengthen supplies
ANSM requests duloxetine manufacturers to increase supply availability.
ANSM (French Medicine Agency) · FrancePRAC September 2026 meeting report (31 August – 3 September)
PUBLIÉ LE 15/07/2026 - MIS À JOUR LE 16/09/2026 Retour d’information sur le PRAC de septembre 2026 (31 août – 3 septembre) Europe Avis du PRAC
ANSM (French Medicine Agency) · FranceWithdrawal of marketing authorisation for Tavneos (avacopan): this medicine can no longer be prescribed or dispensed
EMA recommended withdrawal of Tavneos (avacopan) marketing authorisation in June 2026 due to insufficient benefit to offset known serious hepatic risks.
ANSM (French Medicine Agency) · FranceVerkazia supply shortage: eye drops restricted to children and adolescents only
Verkazia eye drops are restricted to exclusive use in children and adolescents due to supply tensions.
ANSM (French Medicine Agency) · FranceSupply situation update: fluoxetine 20 mg
PUBLIÉ LE 25/09/2026 Point de situation sur les tensions en fluoxétine 20 mg Disponibilité des produits de santé Médicaments
ANSM (French Medicine Agency) · FranceSupply situation update: contrast products
PUBLIÉ LE 30/04/2025 - MIS À JOUR LE 19/08/2026 Point de situation sur les approvisionnements des produits de contraste Disponibilité des produits de santé Médicaments
ANSM (French Medicine Agency) · FranceRisk of confusion between Siklos 100 mg and Siklos 1000 mg: ANSM calls for vigilance during pharmacy dispensing
ANSM alerts to risk of confusion between two strengths of Siklos during pharmacy dispensing and calls for vigilance.
ANSM (French Medicine Agency) · FranceStock shortage of Bicafres 1000 mg gastro-resistant tablets: recommendation for replacement with magistral preparations
Bicafres 1000 mg gastro-resistant tablets are out of stock; ANSM recommends replacement with magistral preparations.
ANSM (French Medicine Agency) · FranceSupply situation update: furosemide 20 mg and 40 mg tablets
ANSM reports on supply tensions affecting furosemide 20 mg and 40 mg tablet formulations in France.
ANSM (French Medicine Agency) · FranceAlepsal: resumption of availability of all dosages
Alepsal medicinal product in all dosages has been returned to availability.
ANSM (French Medicine Agency) · France
Showing 21 of 21 tracked updates
Health-tech only